Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
robyn_harrison [2022/03/29 15:49] liam [Royal Society of Canada] | robyn_harrison [2022/03/29 16:58] (current) liam [COVID-19] |
---|
==== National Advisory Committee on Immunization (2017-current) ==== | ==== National Advisory Committee on Immunization (2017-current) ==== |
| |
Dr. Harrison began as a member of the National Advisory Committee on Immunization in September 2017, and has served as Chair of the Hepatitis and Influenza working groups. On December 19, 2020, she delivered a presentation hosted by CANVax and the National Collaborating Centre for Infectious Diseases to inform health care workers about NACI’s Pfizer-BioNTech COVID-19 vaccine recommendations., She was appointed as the Vice-chair of NACI in June 2021. On June 18, she participated in a French language webinar for the Canadian Association of Physician Assistants on the topic of COVID-19 vaccine interchangeability. | Dr. Harrison began as a member of the [[National Advisory Committee on Immunization]] (NACI) in September 2017, and has served as Chair of the [[Hepatitis]] and [[Influenza]] working groups.((Public Health Agency of Canada. (2021, June 15). //Statement from the Public Health Agency of Canada Announcing the New Chair and Vice-Chair of the National Advisory Committee on Immunization.// Direct Source News; Wayback Machine. https://archive.ph/YBohl)) On December 19, 2020, she delivered a presentation hosted by [[CANVax]] and the [[National Collaborating Centre for Infectious Diseases]] to inform health care workers about NACI’s [[Pfizer-BioNTech COVID-19 vaccine]] recommendations.((NCCID. (2020, December 11). //Recommendations of the National Advisory Committee on Immunization (NACI) on the use of the Pfizer-BioNTech COVID-19 vaccine.// National Collaborating Centre for Infectious Diseases. https://archive.ph/StT0O)) ((NCCID • CCNMI. (2020, December 19). //Recommendations of NACI on the Use of the Pfizer BioNTech COVID 19 Vaccine.// YouTube. https://www.youtube.com/watch?v=0sE-si0XW3k)) She was appointed as the Vice-chair of NACI in June 2021.((Public Health Agency of Canada. (2021, June 7). //Statement from the Public Health Agency of Canada Announcing the New Chair and Vice-Chair of the National Advisory Committee on Immunization.// Government of Canada. https://archive.ph/rWLid)) On June 18, she participated in a French language webinar for the [[Canadian Association of Physician Assistants]] on the topic of [[COVID-19 vaccines|COVID-19 vaccine]] interchangeability.((//Upcoming Events CAPA - ACAM NACI Recommendations on COVID-19 Vaccine Interchangeability.// (2021, June 18). Canadian Association of Physician Assistants. https://archive.ph/O1LY8)) |
| |
| On October 27, 2021, she participated in a webinar discussing flu shots in the 2021/2022 influenza season.((//PHAC webinar for health care providers: seasonal influenza immunization 2021-2022.// (2021, October 20). National Collaborating Centre for Infectious Diseases. https://archive.ph/OhdMH )) The video, posted to the [[YouTube]] channel for the National Collaborating Centre for Infectious Diseases, reveals that the [[Public Health Agency of Canada]] and NACI were aiming for an 80% rate of flu vaccine uptake.((NCCID • CCNMI. (2021, November 29). //PHAC Webinar for Health Care Providers: Seasonal Influenza Immunization 2021-2022.// YouTube. https://web.archive.org/web/20220321165148/https://www.youtube.com/watch?v=Mlg0YDT9nRg)) |
| |
On October 27, 2021, she participated in a webinar discussing flu shots in the 2021/2022 influenza season. The video, posted to the YouTube channel for the National Collaborating Centre for Infectious Diseases, reveals that the Public Health Agency of Canada and NACI were aiming for an 80% rate of flu vaccine uptake. | |
She has received repayment for travel expense totalling less than $1,000 from PHAC since 2017. | She has received repayment for travel expense totalling less than $1,000 from PHAC since 2017. |
| |
==== Antimicrobial Resistance ==== | ==== Antimicrobial Resistance ==== |
| |
Dr. Harrison is an Editorial Contributor/Reviewer for an antimicrobial resistance project called Bugs & Drugs. Other team members include: | Dr. Harrison is an Editorial Contributor/Reviewer for an [[antimicrobial resistance]] project called [[Bugs & Drugs]].((//B&D - The App.// Bugs and Drugs. Retrieved March 24, 2022, from https://archive.ph/h9lq7)) Other team members include: |
| |
* John Conly of the AHS Scientific Advisory Group for COVID-19 | * [[public_health_agencies:canada:John Conly of the AHS Scientific Advisory Group for COVID-19 |
* Andrew Morris of the Ontario COVID-19 Science Advisory Table | * [[public_health_agencies:canada:Andrew Morris]] of the [[Ontario COVID-19 Science Advisory Table]] |
* Lynora Saxinger of the AHS Scientific Advisory Group for COVID-19 | * [[public_health_agencies:canada:Lynora Saxinger]] of the AHS Scientific Advisory Group for COVID-19 |
| |
The project was funded by Alberta Health Services, Alberta Health, and the BC Ministry of Health, Pharmaceutical Services Division. | The project was funded by [[public_health_agencies:canada:Alberta Health Services]], [[Alberta Health]], and the [[BC Ministry of Health]], Pharmaceutical Services Division. |
| |
==== COVID-19 ==== | ==== COVID-19 ==== |
| |
Dr. Harrison is a site investigator for Canadian COVID-19 Cohort Study (CCCS), studying the epidemiology of COVID-19 in Canadian healthcare workers. The specific items for research include the rate of COVID-19 infection, risk factors for infection (occupational and community), antibody levels over time, uptake of vaccines against COVID-19, and psychological impact of working during a pandemic. Dr. Harrison’s study group includes staff working at either Grey Nuns Community Hospital or the University of Alberta Hospital. | Dr. Harrison is a site investigator for [[Canadian COVID-19 Cohort Study]] (CCCS), studying the epidemiology of [[COVID-19]] in Canadian healthcare workers.((//Edmonton - Canadian COVID-19 Cohort Study (CCCS): Study of the epidemiology of COVID-19 in Canadian healthcare workers.// TIBDN: Toronto Invasive Bacterial Diseases Network. Retrieved March 21, 2022, from https://archive.ph/3u0sv)) The specific items for research include the rate of COVID-19 infection, risk factors for infection (occupational and community), antibody levels over time, uptake of [[vaccines]] against COVID-19, and psychological impact of working during a [[pandemic]]. Dr. Harrison’s study group includes staff working at either [[Grey Nuns Community Hospital]] or the [[University of Alberta Hospital]]. |
| |
The CCCS study page bearing Dr. Harrison’s name is hosted on the website for the Toronto Invasive Bacterial Diseases Network at Mount Sinai Hospital, which is funded by “an unrestricted educational grant from Pfizer Canada Inc.” | The CCCS study page bearing Dr. Harrison’s name is hosted on the website for the [[Toronto Invasive Bacterial Diseases Network]] at [[Mount Sinai Hospital]], which is funded by “an unrestricted educational grant from [[pharmaceutical_companies:Pfizer|Pfizer Canada Inc]].” |
| |